Arabic Arabic English English French French German German
dark

Solaris Pharma Receives Approval for First Generic Version of Clindagel® (clindamycin phosphate EQ 1%)

Solaris Pharma Corporation announced today that the Company has received an abbreviated new drug application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA” or “Agency”) for the first generic version of Clindagel® (clindamycin phosphate EQ 1%). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Patient Interactive Systems Minimizes Nurse Burnout & Facilitates Patient Education

Next Post

Kelyniam Global Releases 2nd Quarter 2021 Financials Maintains Profitability – Covid Challenges Continue

Related Posts
Total
0
Share